期刊文献+

伽玛刀联合化疗治疗小细胞肺癌回顾性分析 被引量:1

下载PDF
导出
摘要 目的回顾性分析伽玛刀联合化疗治疗小细胞肺癌(small cell lung cancer,SCLC)的临床疗效,探讨伽玛刀在联合化疗治疗SCLC中的作用。方法选取21例应用伽玛刀联合化疗治疗的小细胞肺癌进行相关资料及疗效分析。结果全组患者完全缓解(CR)6例,部分缓解(PR)11例,无变化(SD)3例,进展(PD)1例,总有效率为81.0%;1年总生存率为75.2%,2年总生存率为33.7%。结论伽玛刀联合化疗治疗小细胞肺癌近期疗效尚可,不良反应低,但对总生存率影响不大,远期疗效有待进一步观察。
出处 《东南国防医药》 2014年第2期189-191,共3页 Military Medical Journal of Southeast China
  • 相关文献

参考文献16

二级参考文献109

  • 1邵亚娟,王颖轶,孟长婷,王毓洲.小细胞肺癌77例治疗及预后分析[J].中国医学科学院学报,2010,32(4):394-397. 被引量:18
  • 2宋丽华,宋现让,张锡芹,齐洁琳,李秀菊,田禾,步兵.小细胞肺癌患者预后因素分析[J].中华肿瘤杂志,2004,26(7):413-416. 被引量:23
  • 3CAO Ka-jia,HUANG Hui-ying,TU Ming-chi,PAN Guo—ying.Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission[J].Chinese Medical Journal,2005(15):1258-1262. 被引量:6
  • 4粟毅.法国波尔多大学医院应用阿霉素、足叶乙甙、异环磷酰胺联合治疗69例小细胞肺癌病例的回顾分析[J].癌症,2006,25(12):1569-1572. 被引量:3
  • 5Govindan R, Page N, Morgensztem D,et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol,2006,24(28) :4539-4544.
  • 6Takada M , Fukuoka M , Kawahara M , et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer:results of the japan clinical oncology group study 9104 [ J]. J Clin Oncol,2002,20(14) :3054-3060.
  • 7De Ruysscher D , Pijls - Johannesma M , Bentzen SM , et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited disease small-cell lung cancer [ J ]. J Clin Oncol, 2006,24 ( 7 ) : 1057-1063.
  • 8Stupp R, Monnerat C, Turrise A ,et al. Small cell lung cancer:state of the art and future perspectives [ J ]. Lung Cancer, 2004,45 (1) : 105-117.
  • 9Murray N ,Turrisi AT. A review of first-line treatment for small cell lung cancer[ J]. J Thorac Oncol,2006,1 ( 3 ) :270-278.
  • 10Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, eqirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase Ⅲ trial with 5 years'follow-up[J]. J Clin Oncol,2002,20(24) : 4665 -4672.

共引文献223

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部